期刊文献+

异长春花碱为主的联合方案治疗晚期非小细胞肺癌的临床研究 被引量:2

Clinical study of the treatment of Advanced non - small cell lung cancer mainly by navelibine combined with chemotherapy
下载PDF
导出
摘要 目的:观察异长春花碱(NVB)加丝裂霉素(MMC)、顺铂(DDP)联合化疗治疗晚期非小细胞肺癌的疗效和毒副作用。方法:52例肺癌中,男性37例,女性15例;初治38例,复治14例;病理为鳞癌29例,腺癌16例,腺鳞癌4例,未分类3例;Ⅲb期33例,Ⅳ期19例。化疗方案为MNP,即MMC6mg/m2D1天静注,NVB25mg/m2D1、8天静注,DDP30mg/m2D1-3天静注。每周期间隔28天,均采用二周期以上评价疗效。结果:完全缓解1例,部分缓解28例,总有效率55.8%;中位缓解期5.2个月,中位生存期11.7个月;主要毒副反应为骨髓抑制。结论:以NVB为主的联合化疗对晚期非小细胞肺癌有较好的疗效和可耐受的毒副作用。 ve: To observe the therapeutic effect and toxic side - effects of the combination chemotherapy with navelbine plus mitomycin c and cisplatin in the treatment of non - small cell lung cancer(NSCLC). Methods: There were totally 52 NSCLC patients, in which male for 37 cases, female for 15 cases. Primary treatment for 38 cases, return treatment for 14 cases. The pathology revealed 29 cases of squamous cell carcinoma, 16 cases of adenocarcinoma, 4 cases of adenosquamous carcinoma, and 3 cases of Unclassified carcinoma. 33 cases had stage Ⅲb disease and 19 had stage Ⅳ . MNP chemotherapeutic regimen: MMC 6mg/m D1, intravenous injection for 1 day, NVB25mg/m2, D1,8, intravenous injection for 2 days, DDP30mg/m2, D1-3, intravenous injection, con-tinuously for 3 days, repeated every 28 days. The evaluation of therapeutic effect was more than 2 cycles. Results:Complete response was observed in 1 patient and partial response was observed in 28 patients with an overall response rate of 55. 8% . The median response duration was 5.2 months and the median survival period was 11.7 months. The principal toxic side- effect was inhibition of bone marrow. Conclusions: Advanced non - small cell lung cancer treated mainly by MNP regimen shows a better therapeutic effect, and toxic side- effects are tolerant.
出处 《临床肿瘤学杂志》 CAS 2001年第4期334-336,共3页 Chinese Clinical Oncology
关键词 非小细胞肺癌 药物疗法 异长春花碱 联合化疗 Non - small cell lung carcinoma ,Drug therapy Navelbine Combined chemotherapy
  • 相关文献

参考文献7

  • 1张湘茹,孙燕.新抗肿瘤药异长春花碱[J].北京医学,1992,14(3):171-176. 被引量:147
  • 2O'Rourke MA. Historical review of trals with vinorebine in NSCLC. Review Oncology, 1998; 11 Suppl. 12:20-27.
  • 3Wozniak AJ, Crowley JJ, Balcerzak SP, et al. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatmen of advanced NSCLC: a Southwest Oncology Group study. J Chin Oncol, 1998,16(7):2459-2465.
  • 4Martoni A, Growley JJ, Balcerzak SP, et al. Randomized clinical trial on high-dose epirubicin plus cis-platinum versus vinorelibne plus cis-platinum in adbanced NSCLC. Lung Cancer, 1998;22:31-38.
  • 5Le Chevalier T, Brisgand D, Douillard J Y et al. Randomised study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small cell lung cancer:results of a European multicentre trial including 612 patients. J Clin Oncol, 1994, 12:360-367.
  • 6Hohneker JA. A summary of vinorelbine (navebine) safety date from north American clinical trials. Semin Oncology, 1994, 21(5:Suppl 10):42
  • 7Rittenberg C N, Gralla R J, Rehmerer T A. Assessing and managing venous irritation associated with vinorelbine tartrate (Navelbine). Oncol, News Forum.1995, 22:707-710

共引文献146

同被引文献10

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部